Cap-specific N6-adenosine methyltransferases and applications in m6A Cap-1 mRNA synthesis
- 1New England Biolabs, Inc.
Abstract
In addition to the 5' Cap-1 structure, the initiating adenosine of mammalian mRNA can be further modified by PCIF1 (Phosphorylated C-terminal domain-interacting factor 1) to form 2'-O,N6-dimethyladenosine (m6A Cap-1). While the biological role is still under investigation, the implications of m6A Cap-1 in mRNA metabolism and viral-host interactions have spurred interest in PCIF1 and m6A Cap-1 as biomarkers, drug targets, and research tools. Here, we identify and characterize two PCIF1-like cap-specific N6-adenosine methyltransferases, PC04 and PC05 and evaluate their applicability in m6A Cap-1 mRNA synthesis in vitro. We found that both enzymes are highly specific to the m7G cap structure and highly active on Cap-1 RNA oligonucleotides and trinucleotide Cap-1 analogs at nanomolar concentrations. We demonstrate that PC04 or PC05 methylation reactions can be incorporated into established post-transcriptional capping and cap analog-based co-transcriptional in vitro transcription (IVT) workflows to produce m6A Cap-1 RNAs. Finally, we show that PC05 can be combined with a previously reported FCE::T7 RNA polymerase fusion to synthesize m6A Cap-1 mRNA from DNA templates in a single step, co-transcriptional manner. The robustness of the PCIF1-like cap N6-adenosine methyltransferases can accelerate research into the biological roles of cap m6A modification and development of highly effective mRNA-based therapeutics.
Related
- Identification of substrates for the skeletal muscle-specific lysine methyltransferases METTL21C and METTL21E
- A modular in vitro multienzyme cascade for the sustainable synthesis of high-value vidarabine 5′-monophosphate from adenosine
- Site-specific m1A Installation by the MTR1 Ribozyme and Modulation of Mitochondrial mRNA Translation in vitro
- Protein expression is amplified by stabilizing mRNA using gene-specific antisense oligonucleotides
- An activator-free method for the synthesis of nucleotide 5′–5′ triphosphate mRNA capping agent
BibTeX
@misc{kneller2026capspecific,
title = {{Cap-specific N6-adenosine methyltransferases and applications in m6A Cap-1 mRNA synthesis}},
author = {D. W. Kneller and D. Nan and S. H. Chan},
howpublished = {bioRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.22.757692},
url = {https://www.biorxiv.org/content/10.64898/2026.10.22.757692v1},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - Cap-specific N6-adenosine methyltransferases and applications in m6A Cap-1 mRNA synthesis
AU - D. W. Kneller
AU - D. Nan
AU - S. H. Chan
PY - 2026
DA - 2026/10/22
PB - bioRxiv
DO - 10.64898/2026.10.22.757692
UR - https://www.biorxiv.org/content/10.64898/2026.10.22.757692v1
AB - In addition to the 5' Cap-1 structure, the initiating adenosine of mammalian mRNA can be further modified by PCIF1 (Phosphorylated C-terminal domain-interacting factor 1) to form 2'-O,N6-dimethyladenosine (m6A Cap-1). While the biological role is still under investigation, the implications of m6A Cap-1 in mRNA metabolism and viral-host interactions have spurred interest in PCIF1 and m6A Cap-1 as biomarkers, drug targets, and research tools. Here, we identify and characterize two PCIF1-like cap-specific N6-adenosine methyltransferases, PC04 and PC05 and evaluate their applicability in m6A Cap-1 mRNA synthesis in vitro. We found that both enzymes are highly specific to the m7G cap structure and highly active on Cap-1 RNA oligonucleotides and trinucleotide Cap-1 analogs at nanomolar concentrations. We demonstrate that PC04 or PC05 methylation reactions can be incorporated into established post-transcriptional capping and cap analog-based co-transcriptional in vitro transcription (IVT) workflows to produce m6A Cap-1 RNAs. Finally, we show that PC05 can be combined with a previously reported FCE::T7 RNA polymerase fusion to synthesize m6A Cap-1 mRNA from DNA templates in a single step, co-transcriptional manner. The robustness of the PCIF1-like cap N6-adenosine methyltransferases can accelerate research into the biological roles of cap m6A modification and development of highly effective mRNA-based therapeutics.
ER -